May 23, 2022
Life Sciences
  • Pfizer and BioNTech’s COVID-19 vaccine was more than 80 percent effective at eliciting a strong immune response in children between the ages of 6 months and 5 years old. Pfizer is seeking an emergency use authorization to vaccinate children five and under. The FDA has said its key advisory committee will meet in June to consider emergency use authorization requests from both Pfizer and Moderna for children in this age group — one of the last groups of Americans still largely ineligible to receive a vaccine. (Articles here, here, here, here, here, and here)